90 related articles for article (PubMed ID: 37654003)
21. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C
J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003
[TBL] [Abstract][Full Text] [Related]
22. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
23. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P; Nikkarinen A; Ek S; Glimelius I
Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
[TBL] [Abstract][Full Text] [Related]
24. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
Front Immunol; 2022; 13():929339. PubMed ID: 36389667
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
[TBL] [Abstract][Full Text] [Related]
26. Targeting macrophages in hematological malignancies: recent advances and future directions.
Li W; Wang F; Guo R; Bian Z; Song Y
J Hematol Oncol; 2022 Aug; 15(1):110. PubMed ID: 35978372
[TBL] [Abstract][Full Text] [Related]
27. CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma.
Freile JÁ; Ustyanovska Avtenyuk N; Corrales MG; Lourens HJ; Huls G; van Meerten T; Cendrowicz E; Bremer E
Biomedicines; 2022 May; 10(5):. PubMed ID: 35625912
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of tumour-associated macrophages.
Pittet MJ; Michielin O; Migliorini D
Nat Rev Clin Oncol; 2022 Jun; 19(6):402-421. PubMed ID: 35354979
[TBL] [Abstract][Full Text] [Related]
29. CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.
Higashi M; Momose S; Takayanagi N; Tanaka Y; Anan T; Yamashita T; Kikuchi J; Tokuhira M; Kizaki M; Tamaru JI
J Pathol Clin Res; 2022 Jul; 8(4):340-354. PubMed ID: 35289116
[TBL] [Abstract][Full Text] [Related]
30. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
Hallek M; Al-Sawaf O
Am J Hematol; 2021 Dec; 96(12):1679-1705. PubMed ID: 34625994
[TBL] [Abstract][Full Text] [Related]
31. Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis.
Le K; Sun J; Khawaja H; Shibata M; Maggirwar SB; Smith MR; Gupta M
Blood Adv; 2021 Jul; 5(14):2863-2878. PubMed ID: 34297045
[TBL] [Abstract][Full Text] [Related]
32. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
Ma MCJ; Tadros S; Bouska A; Heavican T; Yang H; Deng Q; Moore D; Akhter A; Hartert K; Jain N; Showell J; Ghosh S; Street L; Davidson M; Carey C; Tobin J; Perumal D; Vose JM; Lunning MA; Sohani AR; Chen BJ; Buckley S; Nastoupil LJ; Davis RE; Westin JR; Fowler NH; Parekh S; Gandhi M; Neelapu S; Stewart D; Bhalla K; Iqbal J; Greiner T; Rodig SJ; Mansoor A; Green MR
Haematologica; 2022 Mar; 107(3):690-701. PubMed ID: 33792219
[TBL] [Abstract][Full Text] [Related]
33. Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches.
Silkenstedt E; Linton K; Dreyling M
Br J Haematol; 2021 Oct; 195(2):162-173. PubMed ID: 33783838
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.
Chao MP; Takimoto CH; Feng DD; McKenna K; Gip P; Liu J; Volkmer JP; Weissman IL; Majeti R
Front Oncol; 2019; 9():1380. PubMed ID: 32038992
[TBL] [Abstract][Full Text] [Related]
35. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
36. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
[TBL] [Abstract][Full Text] [Related]
37. Notch Signaling Modulates Macrophage Polarization and Phagocytosis Through Direct Suppression of Signal Regulatory Protein α Expression.
Lin Y; Zhao JL; Zheng QJ; Jiang X; Tian J; Liang SQ; Guo HW; Qin HY; Liang YM; Han H
Front Immunol; 2018; 9():1744. PubMed ID: 30105024
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
